An Observational Study Program to Investigate the Effectiveness of Intravitreal Aflibercept in Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion in a Real World Setting

Trial Profile

An Observational Study Program to Investigate the Effectiveness of Intravitreal Aflibercept in Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion in a Real World Setting

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic macular oedema; Retinal vein occlusion
  • Focus Therapeutic Use
  • Acronyms AURIGA
  • Sponsors Bayer
  • Most Recent Events

    • 05 Sep 2017 Planned initiation date changed from 15 Aug 2017 to 30 Sep 2017.
    • 08 Aug 2017 Planned End Date changed from 30 Jun 2020 to 1 Sep 2020.
    • 08 Aug 2017 Planned initiation date changed from 31 Jul 2017 to 15 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top